Combining Targeted Therapy and Immunotherapy Improves Overall Survival in Patients with Anaplastic Thyroid Cancer
University of Texas MD Anderson Cancer CenterResearchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC).